Pharmacological inhibitors of MAPK pathways.

Mitogen-activated protein kinases [MAPKs, also called extracellular signal-regulated kinases (ERKs)] are constituents of numerous signal transduction pathways, and are activated by protein kinase cascades. Intense efforts are under way to develop and evaluate compounds that target components of MAPK pathways. In this article, the current status of inhibitors of MAPK pathways will be presented with a focus on the properties of small-molecule inhibitors of p38, MEK1 and MEK2 protein kinases. Several of these inhibitors are effective in animal models of disease and have advanced to clinical trials for the treatment of inflammatory diseases and cancer. The clinical utility of specifically targeting a subset of cellular signaling cascades and signaling cascades that regulate pleiotropic cellular processes are being evaluated. The results of these efforts have broad implications for the treatment of many diseases.

[1]  G. Bemis,et al.  Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. , 1999, Current medicinal chemistry.

[2]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[3]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[4]  E. A. O'neill,et al.  Molecular basis for p38 protein kinase inhibitor specificity. , 1998, Biochemistry.

[5]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[6]  E. Nishida,et al.  Activation of the Protein Kinase ERK5/BMK1 by Receptor Tyrosine Kinases , 1999, The Journal of Biological Chemistry.

[7]  E. A. O'neill,et al.  The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. , 1998, Biochemistry.

[8]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Powell,et al.  Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[10]  G. Bemis,et al.  The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.

[11]  S. Hubbard.  Structural analysis of receptor tyrosine kinases. , 1999, Progress in biophysics and molecular biology.

[12]  SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[13]  L. Tong,et al.  A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.

[14]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[15]  D E Griswold,et al.  Inhibition of p38 MAP kinase as a therapeutic strategy. , 2000, Immunopharmacology.

[16]  J. Boehm,et al.  New inhibitors of p38 kinase , 2000 .

[17]  J. Siekierka,et al.  RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  E. Goldsmith,et al.  How MAP Kinases Are Regulated (*) , 1995, The Journal of Biological Chemistry.

[19]  E. A. O'neill,et al.  Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. , 1999, Journal of Medicinal Chemistry.

[20]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[21]  Philip R. Cohen,et al.  Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway , 2001, FEBS letters.

[22]  John C. Lee,et al.  SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[23]  M. Karin,et al.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. , 2001, The Journal of clinical investigation.

[24]  P. Cohen,et al.  Effect of SB 203580 on the activity of c-Raf in vitro and in vivo , 1999, Oncogene.

[25]  Ajay,et al.  The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. , 1999, Chemistry & biology.

[26]  N. Neff,et al.  Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway , 1998, The Journal of Neuroscience.

[27]  E. Goldsmith,et al.  The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Greene,et al.  CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family* , 2001, The Journal of Biological Chemistry.

[29]  S. Kassis,et al.  p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. , 1999, Pharmacology & therapeutics.

[30]  P. A. Harris,et al.  The discovery of potent cRaf1 kinase inhibitors. , 2000, Bioorganic & medicinal chemistry letters.

[31]  Paul R. Caron,et al.  Crystal Structure of p38 Mitogen-activated Protein Kinase* , 1996, The Journal of Biological Chemistry.

[32]  L. Johnson,et al.  Active and Inactive Protein Kinases: Structural Basis for Regulation , 1996, Cell.

[33]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[34]  K. Resing,et al.  Pharmacologic inhibitors of MKK1 and MKK2. , 2001, Methods in enzymology.

[35]  Elizabeth J. Goldsmith,et al.  Acquisition of Sensitivity of Stress-activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino Acids within the ATP Binding Pocket* , 1998, The Journal of Biological Chemistry.

[36]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[37]  M. Su,et al.  Kinetic mechanism and ATP‐binding site reactivity of p38γ MAP kinase , 1999 .

[38]  F. Hobbs,et al.  Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.

[39]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[40]  K. Wilson,et al.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.

[41]  M. Murcko,et al.  Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. , 1999, Journal of medicinal chemistry.

[42]  P. Cohen,et al.  Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. , 1998, Chemistry & biology.

[43]  I. McLay,et al.  RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. , 2001, Bioorganic & medicinal chemistry letters.

[44]  R R Osborn,et al.  SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. , 2000, The Journal of pharmacology and experimental therapeutics.

[45]  N. Ahn,et al.  Signal transduction through MAP kinase cascades. , 1998, Advances in cancer research.

[46]  O. Hensens,et al.  Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK. , 1999, The Journal of antibiotics.

[47]  L. Cantley,et al.  Differential MAPK Pathways Utilized for HGF- and EGF-dependent Renal Epithelial Morphogenesis* , 2001, The Journal of Biological Chemistry.

[48]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[49]  D. Williams,et al.  Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. , 1998, Biochemistry.

[50]  S. Sato,et al.  A radicicol-related macrocyclic nonaketide compound, antibiotic LL-Z1640-2, inhibits the JNK/p38 pathways in signal-specific manner. , 1999, Biochemical and biophysical research communications.

[51]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[52]  S. Watson,et al.  Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059 , 1998, The Journal of Biological Chemistry.